argenx(ARGX) Newsfilter·2025-04-08 05:00Core Insights - argenx SE presented 15 abstracts at the 2025 American Academy of Neurology Annual Meeting, showcasing long-term data for VYVGART and VYVGART Hytrulo, demonstrating sustained disease control in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile [1][2][3] Group 1: VYVGART and VYVGART Hytrulo Efficacy - VYVGART and VYVGART Hytrulo show differentiated efficacy and safety profiles, with long-term studies indicating significant quality of life improvements for gMG and CIDP patients [3][5] - ADAPT-NXT data reveal that 75% of gMG patients achieved sustained efficacy, with over 56.5% experiencing minimal symptom expression during the study [7] - ADHERE+ data demonstrate functional improvements in CIDP patients, with significant increases in disability scores and grip strength at week 36 compared to baseline [5][6] Group 2: Ongoing Studies and Pipeline - argenx is conducting label expansion studies for VYVGART in ocular myasthenia gravis (oMG) and seronegative myasthenia gravis (snMG) to reach a broader patient community [2][16] - First-in-human data for ARGX-119, a new clinical candidate targeting neuromuscular junction disorders, show a favorable safety profile, supporting its further development [2][31] - The company aims to address unmet needs in underserved patient communities through its robust neuromuscular pipeline [9][34] Group 3: Commitment to Patient Outcomes - The data presented at AAN reinforce argenx's commitment to the neuromuscular community and solidify VYVGART as a leading biologic for improving patient outcomes [3][4] - The company emphasizes individualized treatment options for gMG patients, showcasing the flexibility of VYVGART dosing schedules [6][7] - Real-world data from the ADHERE Phase 4 study indicate a low rate of CIDP worsening among patients transitioning from IVIg to VYVGART Hytrulo [8]